Drug Profile
XEN D0103
Alternative Names: S 066913; S-66913; XEN-D0103Latest Information Update: 20 Mar 2018
Price :
$50
*
At a glance
- Originator Xention
- Developer Servier; Xention
- Class Antiarrhythmics
- Mechanism of Action Kv1.5 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 14 May 2015 Xention completes a phase II clinical trial in Atrial fibrillation in United Kingdom (EudraCT2013-004456-38)
- 12 Nov 2014 Phase-II clinical trials in Atrial fibrillation in Poland (PO) (EudraCT2014-002333-63)
- 11 Apr 2014 Phase-II clinical trials in Atrial fibrillation in United Kingdom (PO)